Skip to main content
Clinical Trials/DRKS00024581
DRKS00024581
Not yet recruiting
未知

Evaluation of glaucoma or ocular hypertension patients with pre-existing ocular surface disease switched from a preserved prostaglandin analog – timolol fixed combination to a preservative – free latanoprost – timolol fixed combination

Department of Ophthalmology, University hospital center Zagreb0 sites30 target enrollmentMarch 29, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Ocular Hypertension
Sponsor
Department of Ophthalmology, University hospital center Zagreb
Enrollment
30
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 29, 2021
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Department of Ophthalmology, University hospital center Zagreb

Eligibility Criteria

Inclusion Criteria

  • Adult (?18years) patients
  • With open angle galucoma or ocular hypertension that had been controlled (stable IOP \<19mmHg) by commercially available preserved PGA –timolol FC for at least 3 months
  • Stable visual field (based on at least two reliable visual field tests performed within the last 12 months)
  • Central corneal thickness within the range 500\-580µm.
  • mild to moderate hyperaemia based on MacMonnies (scores 1 and 2\)

Exclusion Criteria

  • Best\-corrected visual acuity (BCVA) 0,1 or lower
  • Severe visual field defects (MD 12 dB or higher)
  • Any intraocular surgery (other than filtration surgery performed at least 6 months before screening)
  • Any ocular surface abnormality preventing accurate IOP measurement
  • Acute ocular inflammation
  • Contact lens wearers

Outcomes

Primary Outcomes

Not specified

Similar Trials